Tucatinib, a highly-selective third-generation HER2-TKI, demonstrated compelling intracranial activity in the HER2CLIMB trial, which evaluated tucatinib or placebo in combination with trastuzumab and capecitabine in patients with previously-treated HER2+ breast cancer [108]. The gene discussed is ERBB2; the disease is breast carcinoma.